Home
/
BridgeBio Pharma, Inc.
/
Financials
/
Quarterly
BridgeBio Pharma, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that BridgeBio Pharma, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$120.70M
Oct 29, 2025
Q2
2025
Jun 30, 2025
$110.57M
Aug 5, 2025
Q1
2025
Mar 31, 2025
$116.63M
Apr 29, 2025
Q3
2025
Sep 30, 2024
$2.73M
Oct 29, 2025
Q2
2025
Jun 30, 2024
$2.17M
Aug 5, 2025
Q1
2025
Mar 31, 2024
$211.12M
Apr 29, 2025
Q3
2024
Sep 30, 2023
$4.09M
Nov 12, 2024
Q2
2024
Jun 30, 2023
$1.64M
Aug 1, 2024
Q1
2024
Mar 31, 2023
$1.83M
May 2, 2024
Q3
2023
Sep 30, 2022
$338.0K
Nov 2, 2023
Q2
2023
Jun 30, 2022
$73.75M
Aug 3, 2023
Q1
2023
Mar 31, 2022
$1.69M
May 4, 2023
Q3
2022
Sep 30, 2021
$2.34M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$54.02M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$462.0K
May 5, 2022
Q3
2021
Sep 30, 2020
$8.13M
Nov 4, 2021
Q3
2020
Sep 30, 2019
$26.74M
Nov 5, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2019
Jun 30, 2019
($69.0K)
Aug 14, 2019
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($145.20M)
Oct 29, 2025
Q2
2025
Jun 30, 2025
($134.28M)
Aug 5, 2025
Q1
2025
Mar 31, 2025
($104.37M)
Apr 29, 2025
Q3
2025
Sep 30, 2024
($191.75M)
Oct 29, 2025
Q2
2025
Jun 30, 2024
($175.54M)
Aug 5, 2025
Q1
2025
Mar 31, 2024
$343.0K
Apr 29, 2025
Q3
2024
Sep 30, 2023
($157.69M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($146.10M)
Aug 1, 2024
Q1
2024
Mar 31, 2023
($126.16M)
May 2, 2024
Q3
2023
Sep 30, 2022
($129.12M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($80.18M)
Aug 3, 2023
Q1
2023
Mar 31, 2022
($173.68M)
May 4, 2023
Q3
2022
Sep 30, 2021
($149.50M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($94.02M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($167.50M)
May 5, 2022
Q3
2021
Sep 30, 2020
($119.94M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($124.57M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($102.49M)
May 6, 2021
Q3
2020
Sep 30, 2019
($54.53M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($69.32M)
Aug 11, 2020